Hemab Therapeutics Holdings, Inc.
COAG$1.37B
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaCAMBRIDGE59 employees
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
COAG News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Sutacimig
Congenital Factor VII Deficiency
HMB-002 (Part A)
Von Willebrand Disease (VWD)
HMB-001
Glanzmann Thrombasthenia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sutacimig | Phase 2 | Congenital Factor VII Deficiency | - | - |
HMB-002 (Part A) | Phase 2 | Von Willebrand Disease (VWD) | - | - |
HMB-001 | Phase 2 | Glanzmann Thrombasthenia | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply